Universal Biosensors Licenses SpeeDx's MNAzyme Tech for Point-of-Care MDx Apps | GenomeWeb

Australian diagnostics firm Universal Biosensors said this week that it has non-exclusively licensed fellow Aussie firm SpeeDx's proprietary MNAzyme technology for use in molecular diagnostics applications.

The technology is a "sensitive and highly selective" method for detecting DNA and RNA and, when combined with UBI's diagnostic biosensor technology, will enable the development of a molecular diagnostic platform "that can deliver rapid, low-cost results at the point of care," UBI said.

Financial terms of the deal were not disclosed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.